Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy (semaglutide) injection 2.4 mg, describing the approval as the first and only glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved to treat adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced-calorie diet and increased physical activity. There is an ongoing study to confirm the clinical benefit of Wegovy in adults with MASH, the announcement stated.

MASH represents a significant . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
If you are already a member, log in to your account to access this resource and more.

You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

Market Watch

A snapshot of what’s happening across the industry—a one-stop source for key developments across policy and regulatory changes, service and treatment innovations, technological advancements, industry recognition and accreditation, mergers and acquisitions, leadership shifts, and more.

Filter Options

  • By Categories
  • By Date Range
  • Sort Date By
  • Results Per Page
Clear Filters

  • This field is for validation purposes and should be left unchanged.
  • Max. file size: 98 MB.